A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
NCT06778967 on ClinicalTrials.gov · last registry update 2025-11-25
An unusually large phase 3: 1,100 participants, more than double the 424 typical for the stage. Due to report 11 December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c)(%). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Gan & Lee Pharmaceuticals.
- Sponsor type
- Industry
- Enrollment
- 1,100
- Started
- 2025-02-13
- Primary completion
- 2026-12-11 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Hemoglobin A1c (HbA1c)(%)
Conditions studied
Type 2 Diabetes Mellitus (T2DM)
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.